

NIHR

Nil

The King's Fund

A reflective learning framework for partnering

The framework is based on insights from the early work of the Healthy Communities Together partnerships programme and a rapid synthesis of evidence and theory from reviews of what makes for effective partnerships. Rather than prescribing a series of 'must dos', it offers questions for partnerships to use as a preparatory and reflective tool in their work.

Systematic search: No

June 2022

<https://www.kingsfund.org.uk/publications/learning-framework-for-partnering>

Scottish Medicines Consortium (SMC Advice)

lenvatinib (Kisplyx)

Accepted for restricted use for the treatment of adults with advanced renal cell carcinoma (RCC), in combination with pembrolizumab, as first-line treatment subject to a two-year clinical stopping rule.

Systematic search: No

June 2022

<https://www.scottishmedicines.org.uk/medicines-advice/lenvatinib-kisplyx-abb-smc2476/>

relugolix, estradiol, norethisterone acetate tablets (Ryeqo®)

Accepted for restricted use for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. Restricted to patients who have failed or are unsuitable for conventional therapies (first line treatments), such as tranexamic acid, hormonal contraceptives and intrauterine delivery systems.

Systematic search: No

June 2022

<https://www.scottishmedicines.org.uk/medicines-advice/relugolixestradiolnorethisterone-acetate-ryeqo-full-smc2442/>

abrocitinib (Cibinqo®)

Accepted for restricted use for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. Restricted to patients who have not responded to, or have lost response to, at least one systemic immunosuppressant therapy, or in whom these are contraindicated or not tolerated.

Systematic search: No

June 2022

<https://www.scottishmedicines.org.uk/medicines-advice/abrocitinib-cibinqo-full-smc2431/>

ixekizumab (Taltz®)

NOT recommended for use in the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy or the treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).

Systematic search: No

June 2022

<https://www.scottishmedicines.org.uk/medicines-advice/ixekizumab-taltz-full-smc2440/>

tepotinib (Tepmetko®)

NOT recommended for use for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations.

Systematic search: No

June 2022

<https://www.scottishmedicines.org.uk/medicines-advice/tepotinib-tepmetko-full-smc2457/>

Scottish Government

National Care Service – collection

<https://www.gov.scot/collections/national-care-service/>

Collection of papers setting out key sources of information about social care and related areas in Scotland, to support the development of the National Care Service:

National Care Service - health and demographic profile: evidence

National Care Service - people who access adult social care and unpaid carers: evidence

National Care Service - social care support and service provision: evidence

National Care Service - social care and caring experiences: evidence

National Care Service - adult social care workforce: evidence

National Care Service - adult social care: equality evidence review

National Care Service - children's social services: overview

National Care Service - justice social work: overview

Additional papers also consider relevant services in other countries:

National Care Service - national systems of social care in Nordic and Scandinavian countries: learning and evidence review

National Care Service - SCFNuka (Alaska) and Canterbury (New Zealand) models: integrated care studies

Suicide prevention strategy development: early engagement - summary report

Summary report of views gathered to support development of the new Suicide Prevention Strategy and Action Plan 2022.

Systematic search: No

June 2022

<https://www.gov.scot/publications/new-suicide-prevention-strategy-scotland-early-engagement-summary-report/>

SIGN

Nil

Public Health Scotland

Management of suspected monkeypox in primary and community care (Version 1.1)

This guidance is intended to assist with local pathway arrangements. It is based on the published UKHSA principles for monkeypox control in the UK four nations consensus statement and associated UKHSA guidance documents. Content will be subject to frequent updates.

Systematic search: No

June 2022

<https://www.publichealthscotland.scot/publications/management-of-suspected-monkeypox-in-primary-and-community-care/management-of-suspected-monkeypox-in-primary-and-community-care-version-11>

Monkeypox guidance for health protection teams (Version 1.0)

Systematic search: No

June 2022

<https://www.publichealthscotland.scot/publications/monkeypox-guidance-for-health-protection-teams/monkeypox-guidance-for-health-protection-teams-version-1/>

Review of alcohol marketing restrictions in seven European countries

The review and associated case studies consider alcohol marketing restrictions in Estonia, Finland, France, Ireland, Lithuania, Norway and Sweden (why they are used, how they are monitored and enforced, and how effective they are).

Systematic search: Limited

June 2022

<https://www.publichealthscotland.scot/publications/review-of-alcohol-marketing-restrictions-in-seven-european-countries/review-of-alcohol-marketing-restrictions-in-seven-european-countries-14-june-2022/>

Are the kids alright? Key messages from the third round of the Public Health Scotland COVID-19 Early Years Resilience and Impact Survey (CEYRIS)

Overall, the findings suggest that for a substantial proportion of children in the sample, parents and carers perceive the pandemic to have had a negative impact on child and family health, wellbeing and development. The impacts generally appear to be felt to a greater extent in families from low-income households, who may have already been struggling before the pandemic. The impacts do not appear to be universal, areas that some families report as having a negative impact, others report as having a positive impact. There are areas where the perceived impacts tend to be positive, rather than negative. There are areas where further analysis would be beneficial, which will be presented in future publications.

Systematic search: No

June 2022

<https://www.publichealthscotland.scot/publications/covid-19-early-years-resilience-and-impact-survey-ceyris-report/are-the-kids-alright-key-messages-from-the-third-round-of-the-public-health-scotland-covid-19-early-years-resilience-and-impact-survey/>

Evaluating the impact of Minimum Unit Pricing in Scotland on people who are drinking at harmful levels

There was a marked increase in the prices paid for alcohol by people with alcohol dependence and those drinking at harmful levels after the introduction of MUP. There was no clear evidence found of any change in consumption or severity of dependence although such an effect cannot be ruled out. The study found increased financial strain among some economically vulnerable groups but no clear evidence that it caused wider negative consequences, such as increased crime, use of illicit substances or acute withdrawal.

<https://www.publichealthscotland.scot/publications/evaluating-the-impact-of-minimum-unit-pricing-in-scotland-on-people-who-are-drinking-at-harmful-levels/>

NICE – Guidelines

NG220 Multiple sclerosis in adults: management

Covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.

Systematic search: Limited

June 2022

<https://www.nice.org.uk/guidance/ng220>

NG221 Reducing sexually transmitted infections

Covers interventions to prevent sexually transmitted infections (STIs) in people aged 16 and over. It aims to reduce the transmission of all STIs, including HIV, and includes ways to help increase the uptake of STI testing and vaccines for human papillomavirus (HPV) and hepatitis A and B.

Systematic search: Limited

June 2022

<https://www.nice.org.uk/guidance/ng221>

NG219 Gout: diagnosis and management

Covers the diagnosis and management of gout. It includes recommendations on diagnosing gout, managing flares, long-term management of gout and referral to specialist services.

Systematic search: Limited

June 2022

<https://www.nice.org.uk/guidance/ng219>

NICE - Technology Appraisal Guidance

TA798 Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation

Systematic search: Limited

June 2022

<https://www.nice.org.uk/guidance/ta798>

TA796 Venetoclax for treating chronic lymphocytic leukaemia

Systematic search: Limited

June 2022

<https://www.nice.org.uk/guidance/ta796>

TA794 Diroximel fumarate for treating relapsing–remitting multiple sclerosis

Systematic search: Limited

June 2022

<https://www.nice.org.uk/guidance/ta794>

TA795 Ibrutinib for treating Waldenstrom's macroglobulinaemia

Systematic search: Limited

June 2022

<https://www.nice.org.uk/guidance/ta795>

TA792 Filgotinib for treating moderately to severely active ulcerative colitis

Systematic search: Limited

June 2022

<https://www.nice.org.uk/guidance/ta792>

EPPI Centre

Nil

AHRQ (Agency for Healthcare Research and Quality – USA)

Telehealth for Women’s Preventive Services

Based on 16 studies, outcomes of telehealth interventions compared with in-person or usual care were generally similar for adolescent and adult women presenting for contraceptive care (screening, counselling, provision, follow up care) or receiving services for screening, evaluation, or treatment of interpersonal violence (IPV). Low strength evidence showed that compared with usual care alone, telehealth interventions to supplement in-person care resulted in similar rates as comparators for contraceptive use (oral contraception, condoms, or long-acting reversible contraception) at 6 months, sexually transmitted infection (STI), and pregnancy; impact on abortion rates was unclear. Low strength evidence also showed that compared with usual care, telehealth interventions for IPV services resulted in similar rates of repeat IPV, depression, fear of partner, coercive control, self-efficacy, post-traumatic stress disorder, and safety behaviours; evidence was unclear on harms. No studies evaluated telehealth services for family planning or STI counselling. Three studies indicated the COVID-19 pandemic increased telehealth utilization. Studies did not adequately evaluate factors related to access, health equity, or potential harms of telehealth.

Systematic search: Yes

June 2022

<https://effectivehealthcare.ahrq.gov/products/telehealth-women/research>

Health Foundation

Nil

Canadian Agency for drugs and Technologies in Health (CADTH)

Melatonin for the Treatment of Insomnia in Children and Adolescents

There is some evidence of benefit of melatonin compared with placebo for the short-term treatment of insomnia in children and adolescents with neurodisabilities. The short-term safety profile of melatonin suggested that it was well-tolerated, although some severe adverse events may occur. There was a lack of long-term safety data. The American Academy of Neurology guideline recommends high-grade melatonin should be prescribed for treatment of sleep disturbance in children and adolescents with autism spectrum disorder if first-line treatment with behavioural strategies is not helpful. Evidence comparing the clinical effectiveness of melatonin with prescription sedatives for the treatment of insomnia in children and adolescents was not identified. No evidence was found regarding the cost-effectiveness of melatonin compared with placebo or prescription sedatives for the treatment of insomnia in children and adolescents.

Systematic search: Limited

June 2022

<https://www.cadth.ca/melatonin-treatment-insomnia-children-and-adolescents>

Cost-Effectiveness of Second-Generation Injectable Antipsychotic Drugs

One economic evaluation found that for adults with bipolar I disorder, the second-generation antipsychotic injectable drug aripiprazole is less costly and more effective over a patient’s lifetime, compared to the second-generation antipsychotic oral drug cariprazine. For adults with bipolar I disorder, aripiprazole injections are more effective compared to the second-generation antipsychotic oral drug asenapine.

Systematic search: Limited

June 2022

<https://www.cadth.ca/cost-effectiveness-second-generation-injectable-antipsychotic-drugs>

McGill University Health Centre (Canada)

Nil

Health Information & Quality Authority (Ireland) – Health Technology Assessments

High level review of configuration and reform of Public Health systems in selected countries

HIQA reviewed international best practice and lessons learned regarding the systems and structures that deliver core public health functions in Australia, Canada, Denmark, Finland, Netherlands, New Zealand, Norway, Sweden, England, Northern Ireland, Scotland and Wales.

Systematic search: No

June 2022

<https://www.higa.ie/reports-and-publications/health-technology-assessment/high-level-review-configuration-and-reform>

Campbell Collaboration

Safety interventions for the prevention of accidents in the work place

Findings indicate that occupational safety interventions directed at the group or organisational level are more effective at improving safety and behaviour and reducing accidents at work than interventions directed solely at the individual level. Multifaceted measures are particularly effective when they include elimination, substitution or other engineering controls. Safety regulation and enforcement contribute to the prevention of accidents at work, but with lesser effect.

Systematic search: Yes

June 2022

<https://onlinelibrary.wiley.com/doi/abs/10.1002/cl2.1234>

Glasgow Centre for Population Health

Social Prescribing for Cycling: Key Learning

GCPH were commissioned by Bike for Good to collate and report on evaluation data captured on their 10-week 'Social Prescribing for Cycling' programme. This report highlights key learning from the delivery of the programme and the referral to it by Community Links Practitioners (CLPs) across Glasgow. Although the programme was disrupted due to COVID lockdown measures, staff shortages and challenges relating to how monitoring information was collected, the findings show positive outcomes in terms of cycling confidence and long-term cycling behaviour, mental and physical health benefits and some examples of wider participation in community life. Positive working relationships between Bike for Good staff and CLPs were also reported. Recommendations are offered in relation to the continued delivery, promotion and evaluation of the programme.

Systematic search: No

June 2022

https://www.gcph.co.uk/publications/1042_social_prescribing_for_cycling_key_learning

NICE FORWARD PLANNING – Publications due July 2022

Self harm: assessment, management and preventing recurrence

Clinical Guideline

Social, emotional and mental wellbeing in primary and secondary education

Public health guideline

Urinary tract infection in under 16s: diagnosis and management

Clinical Guideline

Melanoma: assessment and management

Clinical Guideline

Roxadustat for treating anaemia in people with chronic kidney disease

Technology appraisal guidance

Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer

Technology appraisal guidance

Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors

Technology appraisal guidance

Imlifidase for preventing kidney transplant rejection in people with chronic kidney disease

Technology appraisal guidance

Setmelanotide for treating obesity caused by LEPR or POMC deficiency

Technology appraisal guidance

Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides

Technology appraisal guidance

Pembrolizumab for adjuvant treatment of renal cell carcinoma

Technology appraisal guidance

Mepolizumab for previously treated severe chronic rhinosinusitis with nasal polyps

Technology appraisal guidance

Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma

Technology appraisal guidance

Alpelisib in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative, PIK3CA-mutated breast cancer

Technology appraisal guidance